Clinical Trials List
2007-09-01 - 2008-12-31
Phase II
Terminated14
ICD-10I48.0
Paroxysmal atrial fibrillation
ICD-10I48.2
Chronic atrial fibrillation
ICD-10I48.91
Unspecified atrial fibrillation
ICD-9427.31
Atrial fibrillation
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Yu-Jhih Chang Division of Neurology
- 張寓智 Division of Neurology
- 張健宏 Division of Neurology
- Hsiu-Chuan Wu Division of Neurology
- 陳獻宗 Division of Neurology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 鄭正一 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 吳文憲 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 顏學偉 Division of Cardiovascular Diseases
- Tsung-Hsien Lin Division of Cardiovascular Diseases
- 李坤泰 Division of Cardiovascular Diseases
- Ye-Hsu Lu Division of Cardiovascular Diseases
- 李智雄 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yenn-Jiang Lin Division of Cardiovascular Diseases
- Li-Wei Lo Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 程俊傑 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 沈道永 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 葉冠宏 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
115 participants
-
Global
300 participants
